IMRT Course 2016

SABR in stage I histologically proven NSCLC: an Italian multicenter observational study

OVERALL SURVIVAL

2B

1,0

0,8

0,6

0,4

OVERALL SURVIVAL

0,2

% 1 year: 94.0

% 2 years: 81.6

% 3 years: 68.0

0,0

,00

12,00

24,00

36,00

48,00

60,00

72,00

84,00

96,00

Time since enrollement (months)

Number at risk

196 165 107 63 37 15 7 4 1

Ricardi et al, Lung Cancer 2014